BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16445668)

  • 21. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
    Rottmann D; Snir OL; Wu X; Wong S; Hui P; Santin AD; Buza N
    Mod Pathol; 2020 Jan; 33(1):118-127. PubMed ID: 31477811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of her-2/neu amplification/overexpression in OSCC with fluorescence in situ hybridization (FISH) and immunohistochemistry].
    Scheer M; Prange W; Petmecky K; Schirmacher P; Zöller JE; Kübler AC
    Mund Kiefer Gesichtschir; 2003 May; 7(3):138-45. PubMed ID: 12764679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
    Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
    Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
    J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER-2/neu amplification is an independent prognostic factor in gastric cancer.
    Park DI; Yun JW; Park JH; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Yoo CH; Son BH; Cho EY; Chae SW; Kim EJ; Sohn JH; Ryu SH; Sepulveda AR
    Dig Dis Sci; 2006 Aug; 51(8):1371-9. PubMed ID: 16868827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
    Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ
    J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma.
    Xian ZH; Zhang SH; Cong WM; Wu WQ; Wu MC
    J Clin Pathol; 2005 May; 58(5):500-3. PubMed ID: 15858121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
    Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
    J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival and risk factors associated with uterine sarcomas and carcinosarcomas in stage I and II.
    Visnovsky J; Kudela E; Slavik P; Krkoska M; Buocik P; Szepe P; Danko J
    Neuro Endocrinol Lett; 2015; 36(8):750-7. PubMed ID: 26921575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study.
    Schipf A; Mayr D; Kirchner T; Diebold J
    Virchows Arch; 2008 Mar; 452(3):259-68. PubMed ID: 18193277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
    Liu W; Zhong S; Chen J; Yu Y
    J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
    Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
    Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.
    Bansal N; Herzog TJ; Seshan VE; Schiff PB; Burke WM; Cohen CJ; Wright JD
    Obstet Gynecol; 2008 Jul; 112(1):64-70. PubMed ID: 18591309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma.
    Bozzetti C; Personeni N; Nizzoli R; Guazzi A; Flora M; Bassano C; Negri F; Martella E; Naldi N; Franciosi V; Cascinu S
    Cancer; 2003 Oct; 99(5):310-5. PubMed ID: 14579298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation.
    Singh P; Smith CL; Cheetham G; Dodd TJ; Davy ML
    Int J Gynecol Cancer; 2008; 18(6):1344-51. PubMed ID: 18248390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
    Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
    Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
    Giltnane JM; Murren JR; Rimm DL; King BL
    Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
    Saffari B; Jones LA; el-Naggar A; Felix JC; George J; Press MF
    Cancer Res; 1995 Dec; 55(23):5693-8. PubMed ID: 7585656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
    Singer CF; Köstler WJ; Hudelist G
    Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.